Boston, MA – According to filings with the U.S. Securities and Exchange Commission, NFlection Therapeutics is raising $20,000,000.00 in new funding. Sources indicate as part of senior management President, William Hodder played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About NFlection Therapeutics
NFlection is a biopharmaceutical company focused on the development of novel therapies to address the needs of patients with neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks such as keratinocytic epidermal nevi. To address these rare disorders, which are also referred to as RASopathies because they are driven by the aberrant activation of the Ras/Raf/MEK/ERK pathway, we are developing first-in-class MEK (mitogen-activated protein kinase kinase) inhibitors as topical treatments.

To learn more about NFlection Therapeutics, visit http://www.nflectionrx.com/

Contact:
William Hodder, President
617-875-4559
https://www.linkedin.com/in/whodder/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved